Large blood pressure variability and hypertensive cardiac remodeling - Role of cardiac inflammation

Circulation Journal

Volumn 73, Issue 12, 2009, Pages 2198-2203

  Kai, Hisashi ^a   Kudo, Hiroshi ^a   Takayama, Narimasa ^a   Yasuoka, Suguru ^a   Kajimoto, Hidemi ^a   Imaizumi, Tsutomu ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II; Cardiac fibrosis; Cardiac hypertrophy; Macrophage

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; NORADRENALIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

AORTA SINUS; BLOOD PRESSURE MONITORING; BLOOD PRESSURE VARIABILITY; BRAIN INFARCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDITIS; CELL INFILTRATION; CHRONIC INFLAMMATION; DENERVATION; DISEASE EXACERBATION; DOSE RESPONSE; GERIATRIC PATIENT; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART MUSCLE REMODELING; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MACROPHAGE; MONOCYTE; NONHUMAN; PROTEIN EXPRESSION; PULSE PRESSURE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SPONTANEOUSLY HYPERTENSIVE RAT; STROKE; SYMPATHETIC NERVE; SYSTOLIC DYSFUNCTION; TARGET ORGAN; UPREGULATION;

ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; FIBROSIS; HUMANS; HYPERTENSION; MACROPHAGES; MYOCARDITIS; MYOCARDIUM; RATS; RATS, INBRED SHR; RECEPTOR, ANGIOTENSIN, TYPE 1; SYMPATHECTOMY; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 73349115539     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0741     Document Type: Review

References (30)

1. Verdecchia P, Schillaci G, Guerrieri M, Gatteschi C, Benemio G, Boldrini F, et al. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 1990; 81: 528-536.
2. Verdecchia P, Schillaci G, Gatteschi C, Zampi I, Battistelli M, Bartoccini C, et al. Blunted nocturnal fall in blood pressure in hypertensive women with future cardiovascular morbid events. Circulation 1993; 88: 986-992.
3. Kario K, Matsuo T, Kobayashi H, Imiya M, Matsuo M, Shimada K. Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients: Advanced silent cerebrovascular damage in extreme dippers. Hypertension 1996; 27: 130-135.
4. Soylu A, Yazici M, Duzenli MA, Tokac MOK, Gok H. Relation between abnormalities in circadian blood pressure rhythm and target organ damage in normotensives. Circ J 2009; 73: 899-904.
5. Mancia G, Ferrari A, Gregorini L, Parati G, Pomidossi G, Bertinieri G, et al. Blood pressure and heart rate variabilities in normotensive and hypertensive human beings. Circ Res 1983; 53: 96-104.
6. Floras JS, Hassan MO, Jones JV, Osikowska BA, Sever PS, Sleight P. Factors influencing blood pressure and heart rate variability in hypertensive humans. Hypertension 1988; 11: 273-281.
7. Canonico V, De Caprio L, Vigorito C, Forgione L, Tedeschi C, Guarini P, et al. Differences in blood pressure profile between young and elderly hypertensive patients. J Hum Hypertens 1990; 4: 405-409.
8. Zakopoulos NA, Tsivgoulis G, Barlas G, Papamichael C, Spengos K, Manios E, et al. Time rate of blood pressure variation is associated with increased common carotid artery intima-media thickness. Hypertension 2005; 45: 505-512.
9. Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G. Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. J Hypertens1987; 5: 93-98.
10. Palatini P, Penzo M, Racioppa A, Zugno E, Guzzardi G, Anaclerio M, et al. Clinical relevance of nighttime blood pressure and of daytime blood pressure variability. Arch Intern Med 1992; 152: 1855-1860.
11. Frattola A, Parati G, Cuspidi C, Albini F, Mancia G. Prognostic value of 24-hour blood pressure variablity. J Hypertens 1993; 11: 1133-1137.
12. Mancia G, Parati G. Ambulatory blood pressure monitoring and organ damage. Hypertension 2000; 36: 894-900.
13. Mancia G, Parati G, Hennig M, Flatau B, Omboni S, Glavina F, et al. Relation between blood pressure variability and carotid artery damage in hypertension: Baseline data from the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens 2001; 19: 1981-1989.
14. Kim KI, Lee JH, Chang HJ, Cho YS, Youn TJ, Chung WY, et al. Association between blood pressure variability and inflammatory marker in hypertensive patients. Circ J 2008; 72: 293-298.
15. Pringle E, Phillips C, Thijs L, Davidson C, Staessen JA, de Leeuw PW, et al. Systolic blood pressure variability as a risk factor for stroke and cardiovascular mortality in the elderly hypertensive population. J Hypertens 2003; 21: 2251-2257.
16. Eto M, Toba K, Akishita M, Kozaki K, Watanabe T, Kim S, et al. Impact of blood pressure variability on cardiovascular events in elderly patients with hypertension. Hypertens Res 2005; 28: 1-7.
17. Kudo H, Kai H, Kajimoto H, Koga M, Takayama N, Mori T, et al. Exaggerated blood pressure variability superimposed on hypertension aggravates cardiac remodeling in rats via angiotensin II system-mediated chronic inflammation. Hypertension 2009; 54: 832-838.
18. Lanfranchi PA, Somers VK. Arterial baroreflex function and cardiovascular variability: Interactions and implications. Am J Physiol Regul Integr Comp Physiol 2002; 283: R815-R826.
19. Monahan KD. Effect of aging on baroreflex function in humans. Am J Physiol Regul Integr Comp Physiol 2007; 293: R1-R12.
20. Krieger EM. Neurogenic hypertension in rat. Circ Res 1964; 15: 511-521.
21. van Vliet BN, Hu L, Scott T, Chafe L, Montani JP. Cardiac hypertrophy and telemetered blood pressure 6 wk after baroreceptor denervation in normotensive rats. Am J Physiol 1996; 271: R1759-R1769.
22. van Vliet BN, Chafe LL, Montani JP. Contribution of baroreceptors and chemoreceptors to ventricular hypertrophy produced by sinoaortic denervation in rats. J Physiol 1999; 516: 885-895.
23. Díez J. Diagnosis and treatment of myocardial fibrosis in hypertensive heart disease. Circ J 2008; 72(Suppl A): A-8-A-12.
24. Kai H, Griendling KK, Lassegue B, Ollerenshaw JD, Runge MS, Alexander RW. Agonist-induced phosphorylation of the vascular type 1 angiotensin II receptors. Hypertension 1994; 24: 523-527.
25. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, et al. Transforming growth factor-β function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 2002; 106: 130-135.
26. Kuwahara F, Kai H, Tokuda K, Niiyama H, Tahara N, Kusaba K, et al. Roles of intercellular adhesion molecule-1 in hypertensive cardiac remodeling. Hypertension 2003; 41: 819-823.
27. Tokuda K, Kai H, Kuwahara F, Yasukawa H, Tahara N, Kudo H, et al. Pressure-independent effects of angiotensin II on hypertensive myocardial fibrosis. Hypertension 2004; 43: 499-503.
28. Kuwahara F, Kai H, Tokuda K, Takeya M, Takeshita A, Egashira K, et al. Hypertensive myocardial fibrosis and diastolic dysfunction-another model of inflammation. Hypertension 2004; 43: 739-745.
29. Kai H, Mori T, Tokuda K, Takayama N, Tahara N, Takemiya K, et al. Pressure overload-induced transient oxidative stress mediates perivascular inflammation and cardiac fibrosis through angiotensin II. Hypertens Res 2006; 29: 711-718.
30. Goldstein DS. Plasma catecholamines and essantial hypertension. An analytical review. Hypertension 1983; 5: 86-99.